Diana Brainard
Amministratore Delegato presso ALLOVIR, INC.
Patrimonio netto: 665 276 $ in data 30/04/2024
Posizioni attive di Diana Brainard
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ALLOVIR, INC. | Direttore/Membro del Consiglio | 01/07/2020 | - |
| Amministratore Delegato | 17/05/2021 | - | |
| Independent Dir/Board Member | 01/04/2019 | - | |
| NEKTAR THERAPEUTICS | Direttore/Membro del Consiglio | 11/11/2021 | - |
| Independent Dir/Board Member | 11/11/2021 | - | |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Direttore/Membro del Consiglio | 08/03/2022 | - |
| Independent Dir/Board Member | 08/03/2022 | - | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investitore di Private Equity | - | - |
Storia della carriera di Diana Brainard
Precedenti posizioni note di Diana Brainard
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2015 | 01/01/2021 |
Formazione di Diana Brainard
| Brown University | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 8 |
Posizioni
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| Aziende private | 2 |
|---|---|
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
- Borsa valori
- Insiders
- Diana Brainard
- Esperienza
